Kidney Risk Variants and Proteomics.

Title Kidney Risk Variants and Proteomics.
Publication TypeJournal Article
Year of Publication2022
AuthorsChen, TK, Surapaneni, AL, Arking, DE, Ballantyne, CM, Boerwinkle, E, Chen, J, Coresh, J, Köttgen, A, Susztak, K, Tin, A, Yu, B, Grams, ME
JournalClin J Am Soc Nephrol
Volume17
Issue5
Pagination684-692
Date Published2022 May
ISSN1555-905X
KeywordsAnimals, Apolipoprotein L1, Creatinine, Female, Genetic Predisposition to Disease, Genotype, Humans, Kidney, Male, Matrix Metalloproteinase 2, Mice, Proteoglycans, Proteomics, Renal Insufficiency, Chronic, Risk Factors, Tissue Inhibitor of Metalloproteinase-2
Abstract

BACKGROUND AND OBJECTIVES: The risk variants (G1 and G2) are associated with kidney disease among Black adults, but the clinical presentation is heterogeneous. In mouse models and cell systems, increased gene expression of G1 and G2 confers cytotoxicity. How risk variants relate to the circulating proteome warrants further investigation.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 461 African American Study of Kidney Disease and Hypertension (AASK) participants (mean age: 54 years; 41% women; mean GFR: 46 ml/min per 1.73 m), we evaluated associations of risk variants with 6790 serum proteins (measured SOMAscan) using linear regression models. Covariates included age, sex, percentage of European ancestry, and protein principal components 1-5. Associated proteins were then evaluated as mediators of -associated risk for kidney failure. Findings were replicated among 875 Atherosclerosis Risk in Communities (ARIC) study Black participants (mean age: 75 years; 66% women; mean eGFR: 67 ml/min per 1.73 m).

RESULTS: In the AASK study, having two (versus zero or one) risk alleles was associated with lower serum levels of APOL1 (=3.11E-13; =3.12E-06 [two aptamers]), APOL2 (1.45E-10), CLSTN2 (=2.66E-06), MMP-2 (=2.96E-06), SPOCK2 (=2.57E-05), and TIMP-2 (=2.98E-05) proteins. In the ARIC study, risk alleles were associated with APOL1 (=1.28E-11); MMP-2 (=0.004) and TIMP-2 (=0.007) were associated only in an additive model, and APOL2 was not available. high-risk status was associated with a 1.6-fold greater risk of kidney failure in the AASK study; none of the identified proteins mediated this association. APOL1 protein levels were not associated with kidney failure in either cohort.

CONCLUSIONS: risk variants were strongly associated with lower circulating levels of APOL1 and other proteins, but none mediated the -associated risk for kidney failure. APOL1 protein level was also not associated with kidney failure.

DOI10.2215/CJN.14701121
Alternate JournalClin J Am Soc Nephrol
PubMed ID35474272
PubMed Central IDPMC9269576
Grant ListR01 DK108803 / DK / NIDDK NIH HHS / United States
P30 DK079310 / DK / NIDDK NIH HHS / United States
K08 DK117068 / DK / NIDDK NIH HHS / United States
R01 HL134320 / HL / NHLBI NIH HHS / United States
K24 HL155861 / HL / NHLBI NIH HHS / United States
P30 ES030285 / ES / NIEHS NIH HHS / United States
R01 DK124399 / DK / NIDDK NIH HHS / United States

Similar Publications